ClinicalTrials.gg
CompletedNCT03343704Updated Feb 25, 2025Results posted

This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding

A Phase 3 interventional study of Idarucizumab in Hemorrhage, sponsored by Boehringer Ingelheim. Completed at 13 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 97 studies in Hemorrhage with a site in China — 27 open to participants now, 29 under way, 5 of them phase 3. Hemorrhage · China.

Enrollment
74th of 77
19 · median 200
Started
2018
with 7 others
Phase 3
17 of 97
5 open now
Registered
37th of 97
by date

Among the 97 studies in Hemorrhage with a site in China, this one is the 74th largest by enrollment of the 77 interventional ones that give a count, is one of 8 that started in 2018, is one of 17 in phase 3, and was the 37th registered.

Hemorrhage

1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.

Browse Hemorrhage studies →

Open to participants now

27 of the 97 studies in Hemorrhage with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in Hemorrhage with a site in China, or all of them as a file.
02

Study summary

The primary objective is to demonstrate reversal of the anticoagulant effect of dabigatran in patients treated with dabigatran etexilate who have uncontrolled or life-threatening bleeding requiring urgent intervention, and in patients treated with dabigatran etexilate who require emergency surgery or other invasive procedure.

The secondary objectives are to assess the reduction or cessation of bleeding, evaluate the clinical outcomes, safety and the pharmacokinetics of dabigatran in the presence of idarucizumab.

03

Conditions studied

  • Hemorrhage

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years at screening.
  • Male or female patients. Women of (WOCBP) and men able to father a child must be ready and able to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.
  • Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial
  • Currently taking dabigatran etexilate
  • They meet the following criteria:

    • Group A: Overt bleeding judged by the physician to require a reversal agent. OR
    • Group B: A condition requiring emergency surgery or invasive procedure where adequate hemostasis is required. Emergency is defined as within the following 8 hours.

Exclusion criteria

Exclusion criteria:

Group A:

  • Patients with minor bleeding (e.g. epistaxis, hematuria) who can be managed with standard supportive care.
  • Patients with no clinical signs of bleeding.
  • to study medication including known to the drug or its (subjects with hereditary fructose intolerance may react to sorbitol).

Group B:

  • A surgery or procedure which is elective or where the risk of uncontrolled or unmanageable bleeding is low.
  • Contraindications to study medication including known hypersensitivity to the drug or its excipients (subjects with hereditary fructose intolerance may react to sorbitol).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Group A - patients with uncontrolled or life-threatening bleeding

    Drug: Idarucizumab

  • Experimental
    Group B - patients not bleeding but requiring emergency surgery or invasive procedure

    Drug: Idarucizumab

Interventions

  • Intravenous

    Also known as: PRAXBIND, Praxbind, Prizbind

06

What researchers measure

Primary outcomes

  1. Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Ecarin Clotting Time

    Maximum reversal of anticoagulant effect of dabigatran based on central laboratory determination of ecarin clotting time is reported. The maximum reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If the calculated reversal is \> 100, it was set to 100. 100% ULN is 41.26 seconds.

    Time frame: From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.

  2. Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Diluted Thrombin Time

    Maximum reversal of anticoagulant effect of dabigatran based on central laboratory determination of diluted thrombin time is reported. The maximum reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If the calculated reversal is \> 100, it was set to 100. 100% ULN is 35.54 seconds.

    Time frame: From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.

Secondary outcomes

  1. Percentage of Participants Achieving Cessation of Bleeding Within 24 Hours After Completion of Second Infusion (for Group A Only)

    Percentage of participants achieving cessation of bleeding within 24 hours after completion of second infusion for Group A is reported.

    Time frame: Up to 24 hours after the completion of the second infusion on Day 1 of the treatment period.

  2. Number of Participants With Major Bleeding (for Group B Only) Intra-operatively and up to 24 Hours Post-surgery

    Number of participants with major bleeding (for Group B only) intra-operatively and up to 24 hours post-surgery per International Society for Thrombosis and Hemostasis (ISTH) classification is reported.

    Time frame: Up to 24 hours post-surgery.

  3. Minimum Unbound Sum Dabigatran Concentrations Since the End of First Infusion up to 4 Hours After the Completion of the Last Infusion (Cmin,1)

    Minimum unbound sum dabigatran concentrations since the end of first infusion up to 4 hours after the completion of the last infusion (Cmin,1) is reported.

    Time frame: Just prior to the second infusion (last infusion) and 10 minutes (min), 30 min, 1 hour (h), 2 h, and 4 h after the end of the second infusion.

  4. Maximum Reversal of Anticoagulation as Measured by Activated Partial Thromboplastin Time (aPTT)

    Maximum reversal of anticoagulation as measured by activated partial thromboplastin time (aPTT) is reported. The reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If the calculated reversal is \> 100, it was set to 100. 100% ULN is 39.80 seconds.

    Time frame: From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.

  5. Maximum Reversal of Anticoagulation as Measured by Thrombin Time (TT)

    Maximum reversal of anticoagulation as measured by thrombin time (TT) is reported. The reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If calculated reversal is \> 100, it was set to 100. 100% ULN is 14.22 seconds.

    Time frame: From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.

  6. Numbers of Participants With Any Adverse Events - on Treatment

    Numbers of participants with any adverse events during on treatment period is reported.

    Time frame: Since the first infusion up until 5 days after the completion of the second infusion.

  7. Numbers of Participants With Any Adverse Events - Including Post Treatment Period

    Numbers of participants with any adverse events until end of study is reported.

    Time frame: Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.

  8. Number of Participants With Serious Adverse Events - on Treatment

    Number of participants with Serious adverse events during on treatment period is reported.

    Time frame: Since the first infusion up until 5 days after the completion of the second infusion.

  9. Number of Participants With Serious Adverse Events - Including Post Treatment Period

    Number of participants with Serious adverse events until the end of study is reported.

    Time frame: Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.

  10. Number of Participants With Drug-related Adverse Events - on Treatment

    Numbers of patients with drug-related adverse events during on treatment period is reported.

    Time frame: Since the first infusion up until 5 days after the completion of the second infusion.

  11. Number of Participants With Drug-related Adverse Events - Including Post Treatment Period

    Numbers of patients with drug-related adverse events until end of study is reported.

    Time frame: Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.

  12. Number of Participants With Immune Reaction Adverse Event - on Treatment

    Number of participants with immune reaction adverse event during on treatment period is reported.

    Time frame: Since the first infusion up until 5 days after the completion of the second infusion.

  13. Number of Participants With Immune Reaction Adverse Event - Including Post Treatment Period

    Number of participants with immune reaction adverse event until end of study is reported.

    Time frame: Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.

  14. Number of Participants With Thrombotic Events - on Treatment

    Number of participants with thrombotic events (ischemic stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis, systemic embolism) during on treatment period is reported.

    Time frame: Since the first infusion up until 5 days after the completion of the second infusion.

  15. Number of Participants With Thrombotic Events - Including Post Treatment Period

    Number of participants with thrombotic events (ischemic stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis, systemic embolism) until end of study is reported.

    Time frame: Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.

07

Results

Posted Aug 20, 2021

Participant flow

This study was to demonstrate the reversal of the anticoagulant effects of dabigatran by intravenous administration of idarucizumab in patients treated with dabigatran etexilate who had uncontrolled bleeding or required emergency surgery or procedures over treatment period of 1 day following by 30 days follow-up.

Participant flow — Overall Study
MilestoneGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure
Started136
Completed124
Not completed12
Withdrew: Refused to complete follow up01
Withdrew: Death01
Withdrew: Reluctant to collect blood and received telephone follow up10

Outcome measures

PrimaryMaximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Ecarin Clotting Time

Maximum reversal of anticoagulant effect of dabigatran based on central laboratory determination of ecarin clotting time is reported. The maximum reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If the calculated reversal is \> 100, it was set to 100. 100% ULN is 41.26 seconds.

Time frame:
From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.
Reported as:
Median · Percentage
Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Ecarin Clotting Time
PercentageGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive ProcedureTotal
Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Ecarin Clotting Time100.0 (100.0 to 100.0)100.0 (96.8 to 100.0)100.0 (100.0 to 100.0)
PrimaryMaximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Diluted Thrombin Time

Maximum reversal of anticoagulant effect of dabigatran based on central laboratory determination of diluted thrombin time is reported. The maximum reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If the calculated reversal is \> 100, it was set to 100. 100% ULN is 35.54 seconds.

Time frame:
From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.
Reported as:
Median · Percentage
Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Diluted Thrombin Time
PercentageGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive ProcedureTotal
Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Diluted Thrombin Time100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
SecondaryPercentage of Participants Achieving Cessation of Bleeding Within 24 Hours After Completion of Second Infusion (for Group A Only)

Percentage of participants achieving cessation of bleeding within 24 hours after completion of second infusion for Group A is reported.

Time frame:
Up to 24 hours after the completion of the second infusion on Day 1 of the treatment period.
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Cessation of Bleeding Within 24 Hours After Completion of Second Infusion (for Group A Only)
Percentage of participantsGroup A - Patients With Uncontrolled or Life-threatening Bleeding
Percentage of Participants Achieving Cessation of Bleeding Within 24 Hours After Completion of Second Infusion (for Group A Only)55.6
SecondaryNumber of Participants With Major Bleeding (for Group B Only) Intra-operatively and up to 24 Hours Post-surgery

Number of participants with major bleeding (for Group B only) intra-operatively and up to 24 hours post-surgery per International Society for Thrombosis and Hemostasis (ISTH) classification is reported.

Time frame:
Up to 24 hours post-surgery.
Reported as:
Count of participants · Participants
Number of Participants With Major Bleeding (for Group B Only) Intra-operatively and up to 24 Hours Post-surgery
ParticipantsGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure
Minor0
Major1
Major, Life -Threatening or Fatal0
Not assessable0
SecondaryMinimum Unbound Sum Dabigatran Concentrations Since the End of First Infusion up to 4 Hours After the Completion of the Last Infusion (Cmin,1)

Minimum unbound sum dabigatran concentrations since the end of first infusion up to 4 hours after the completion of the last infusion (Cmin,1) is reported.

Time frame:
Just prior to the second infusion (last infusion) and 10 minutes (min), 30 min, 1 hour (h), 2 h, and 4 h after the end of the second infusion.
Reported as:
Geometric mean · nanogram per milliliter
Minimum Unbound Sum Dabigatran Concentrations Since the End of First Infusion up to 4 Hours After the Completion of the Last Infusion (Cmin,1)
nanogram per milliliterGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure
Minimum Unbound Sum Dabigatran Concentrations Since the End of First Infusion up to 4 Hours After the Completion of the Last Infusion (Cmin,1)1 ± 01 ± 0
SecondaryMaximum Reversal of Anticoagulation as Measured by Activated Partial Thromboplastin Time (aPTT)

Maximum reversal of anticoagulation as measured by activated partial thromboplastin time (aPTT) is reported. The reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If the calculated reversal is \> 100, it was set to 100. 100% ULN is 39.80 seconds.

Time frame:
From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.
Reported as:
Median · Percentage
Maximum Reversal of Anticoagulation as Measured by Activated Partial Thromboplastin Time (aPTT)
PercentageGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive ProcedureTotal
Maximum Reversal of Anticoagulation as Measured by Activated Partial Thromboplastin Time (aPTT)100 (67.9 to 100.0)100 (98.3 to 100.0)100 (98.3 to 100.0)
SecondaryMaximum Reversal of Anticoagulation as Measured by Thrombin Time (TT)

Maximum reversal of anticoagulation as measured by thrombin time (TT) is reported. The reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If calculated reversal is \> 100, it was set to 100. 100% ULN is 14.22 seconds.

Time frame:
From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.
Reported as:
Median · Percentage
Maximum Reversal of Anticoagulation as Measured by Thrombin Time (TT)
PercentageGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive ProcedureTotal
Maximum Reversal of Anticoagulation as Measured by Thrombin Time (TT)100 (100.0 to 100.0)100 (100.0 to 100.0)100 (100.0 to 100.0)
SecondaryNumbers of Participants With Any Adverse Events - on Treatment

Numbers of participants with any adverse events during on treatment period is reported.

Time frame:
Since the first infusion up until 5 days after the completion of the second infusion.
Reported as:
Count of participants · Participants
Numbers of Participants With Any Adverse Events - on Treatment
ParticipantsGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure
Numbers of Participants With Any Adverse Events - on Treatment116
SecondaryNumbers of Participants With Any Adverse Events - Including Post Treatment Period

Numbers of participants with any adverse events until end of study is reported.

Time frame:
Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.
Reported as:
Count of participants · Participants
Numbers of Participants With Any Adverse Events - Including Post Treatment Period
ParticipantsGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure
Numbers of Participants With Any Adverse Events - Including Post Treatment Period136
SecondaryNumber of Participants With Serious Adverse Events - on Treatment

Number of participants with Serious adverse events during on treatment period is reported.

Time frame:
Since the first infusion up until 5 days after the completion of the second infusion.
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events - on Treatment
ParticipantsGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure
Number of Participants With Serious Adverse Events - on Treatment31
SecondaryNumber of Participants With Serious Adverse Events - Including Post Treatment Period

Number of participants with Serious adverse events until the end of study is reported.

Time frame:
Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events - Including Post Treatment Period
ParticipantsGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure
Number of Participants With Serious Adverse Events - Including Post Treatment Period73
SecondaryNumber of Participants With Drug-related Adverse Events - on Treatment

Numbers of patients with drug-related adverse events during on treatment period is reported.

Time frame:
Since the first infusion up until 5 days after the completion of the second infusion.
Reported as:
Count of participants · Participants
Number of Participants With Drug-related Adverse Events - on Treatment
ParticipantsGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure
Number of Participants With Drug-related Adverse Events - on Treatment21
SecondaryNumber of Participants With Drug-related Adverse Events - Including Post Treatment Period

Numbers of patients with drug-related adverse events until end of study is reported.

Time frame:
Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.
Reported as:
Count of participants · Participants
Number of Participants With Drug-related Adverse Events - Including Post Treatment Period
ParticipantsGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure
Number of Participants With Drug-related Adverse Events - Including Post Treatment Period21
SecondaryNumber of Participants With Immune Reaction Adverse Event - on Treatment

Number of participants with immune reaction adverse event during on treatment period is reported.

Time frame:
Since the first infusion up until 5 days after the completion of the second infusion.
Reported as:
Count of participants · Participants
Number of Participants With Immune Reaction Adverse Event - on Treatment
ParticipantsGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure
Number of Participants With Immune Reaction Adverse Event - on Treatment30
SecondaryNumber of Participants With Immune Reaction Adverse Event - Including Post Treatment Period

Number of participants with immune reaction adverse event until end of study is reported.

Time frame:
Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.
Reported as:
Count of participants · Participants
Number of Participants With Immune Reaction Adverse Event - Including Post Treatment Period
ParticipantsGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure
Number of Participants With Immune Reaction Adverse Event - Including Post Treatment Period30
SecondaryNumber of Participants With Thrombotic Events - on Treatment

Number of participants with thrombotic events (ischemic stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis, systemic embolism) during on treatment period is reported.

Time frame:
Since the first infusion up until 5 days after the completion of the second infusion.
Reported as:
Count of participants · Participants
Number of Participants With Thrombotic Events - on Treatment
ParticipantsGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure
Number of Participants With Thrombotic Events - on Treatment11
SecondaryNumber of Participants With Thrombotic Events - Including Post Treatment Period

Number of participants with thrombotic events (ischemic stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis, systemic embolism) until end of study is reported.

Time frame:
Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.
Reported as:
Count of participants · Participants
Number of Participants With Thrombotic Events - Including Post Treatment Period
ParticipantsGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure
Number of Participants With Thrombotic Events - Including Post Treatment Period23

Adverse events

Collected over Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A - Patients With Uncontrolled or Life-threatening Bleeding0/13 (0%)7/13 (53.8%)13/13 (100%)
Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure1/6 (16.7%)3/6 (50%)6/6 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure
ThrombocytopeniaBlood and lymphatic system disorders0/131/6
Cardiac failureCardiac disorders0/131/6
Cardiac failure chronicCardiac disorders0/131/6
Gastrointestinal haemorrhageGastrointestinal disorders2/131/6
Multiple organ dysfunction syndromeGeneral disorders0/131/6
Hepatic function abnormalHepatobiliary disorders0/131/6
PneumoniaInfections and infestations1/131/6
SeizureNervous system disorders0/131/6
Thalamic infarctionNervous system disorders0/131/6
DeliriumPsychiatric disorders2/130/6
Most frequent other events
Showing 10 of 106
Most frequent other events
EventGroup A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure
AnaemiaBlood and lymphatic system disorders3/133/6
ThrombocytopeniaBlood and lymphatic system disorders0/132/6
DiarrhoeaGastrointestinal disorders2/132/6
InfectionInfections and infestations2/132/6
Neutrophil percentage increasedInvestigations0/132/6
White blood cell count increasedInvestigations0/132/6
HypoalbuminaemiaMetabolism and nutrition disorders3/132/6
ConstipationGastrointestinal disorders4/130/6
PyrexiaGeneral disorders3/130/6
HypokalaemiaMetabolism and nutrition disorders3/130/6

Baseline characteristics

Treated set (TS): include all patients who are administered with idarucizumab.

Age, Continuous
Age, Continuous(Years)Group A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive ProcedureTotal
Mean75.4 ± 12.362.8 ± 10.671.4 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)Group A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive ProcedureTotal
Female549
Male8210
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group A - Patients With Uncontrolled or Life-threatening BleedingGroup B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive ProcedureTotal
American Indian or Alaska Native000
Asian13619
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

13 sites
  • Beijing AnZhen Hospital
    Beijing, 100029, China
  • Peking University First Hospital
    Beijing, 100034, China
  • Cardiovascular Institute and Fu Wai Hospital
    Beijing, 100037, China
  • First Affiliated Hospital of Dalian Medical University
    Dalian, 116011, China
  • Guangdong Provincial People's Hospital
    Guangzhou, 510080, China
  • Sun yet-sen Memorial Hospital, Sun yet-sen Univesity
    Guangzhou, 510288, China
  • 2nd Affiliated Hosp Zhejiang University College of Medical
    Hangzhou, 310009, China
  • Zhejiang Province People's Hospital
    Hangzhou, 310014, China
  • The Second Affiliated Hospital to Nanchang University
    Nanchang, 330006, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu Province, 210029, China
  • Shanghai First People's Hospital
    Shanghai, 200080, China
  • The First Affiliated Hospital of Xinjiang Medical University
    Urumqi, 830054, China
  • The First Affiliated Hospital of Wenzhou Med College
    Wenzhou, 325000, China
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Jul 2020, 27 months.

Results were first posted in Aug 2021, 1 year 1 month after primary completion.

Of 72 phase 3 interventional studies under Hemorrhage, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2017
First posted
Nov 17, 2017
StartActual
Mar 26, 2018
Primary completionActual
Jul 2, 2020
CompletionActual
Jul 2, 2020
Results first posted
Aug 20, 2021
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03343704
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Mar 26, 2018
Primary completion
Jul 2, 2020
Completion
Jul 2, 2020
Results posted
Aug 20, 2021
Last update
Feb 25, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idarucizumab

Start the discussion